Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

The in vivo results of QPI-1007 mark a new era for Quark. We can now rely solely on internally-developed novel compositions and proprietary siRNA structures to develop products that have the potential to provide greater efficacy than current treatments. The breadth of our new structures allows us to selectively pick the most efficacious, stable siRNA structure, which is the most suitable for the specific sequence."

Dr. Logan stated, "QPI-1007 displayed significant neuroprotective activity compared to untreated controls and two different control siRNA molecules in our in vivo model. These results are very exiting. They show that QPI-1007 is a promising drug for ocular neuroprotection."

Dr. Di Polo commented, "The characteristic visual field changes and loss of vision in glaucoma are caused by the selective degeneration of retinal ganglion cells. Our results suggest that QPI-1007 may be an effective neuroprotective therapy for retinal ganglion cells in acute injuries such as non-artheritic ischemic optic neuropathy, and also in slow-progressing chronic optic nerve injuries such as glaucoma. QPI-1007 has the potential to serve an unmet medical need for these indications."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801, licensed to Pfizer. In
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser ... a $99 treatment special. Dr. Brandeis, focus is in providing ... offering expert medical advice to all patients. " ... in the presence of tattoo regret and patients seeking removal ...
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ... the scaphoid and lunate while allowing some rotation between ...
(Date:1/14/2014)... --  NuAire , a manufacturer of ergonomically designed laboratory ... Hitachi Koki of Japan to ... North America . NuAire will utilize its network ... and Canada to offer assistance ... training, pricing, as well as after sale service for the ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Today FRC Action joined 19 pro-life groups in a letter sent to Food ... consideration for FDA approval that can cause abortions but is misleadingly labeled as an "emergency ... Tom McClusky ... the following comments: , , , ...
... INDIANAPOLIS , July 28 Eli Lilly and Company (NYSE: ... the Federal Circuit has upheld a prior ruling by the U.S. District Court ... invalid. , , , ... ruling by the U.S. Court of Appeals regarding Gemzar,s method-of-use patent. We continue ...
Cached Medicine Technology:FRC Action and Pro-Life Coalition Urge the FDA to Reject New Abortion-Causing Drug 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... and the University of Queensland’s researchers have revealed that the ... than parents or friends // as far as habits like ... family tend to follow the example of their older siblings ... the University of Washington studied the role played by peers, ...
... flow for fighting bird flu on Friday, and the World Bank ... a global scale.// ,Most of the funds would be needed ... Central Asia, and then Africa. Latin America is considered low risk ... would most likely originate from an infection in North America. ...
... pounds a very low calories diet can help the heart age ... said to be the first ever human trial study. // ... that demonstrate the cardiac benefits of a restricted calorie diet. ... of the Caloric Restriction Society, ages 41 to 64, who consume ...
... of Cardiovascular Disease have for the first time ... using X-ray crystallography. X-ray crystallography technique // is ... by determining the x-ray diffraction patterns of the ... new discovery will help a lot in understanding ...
... to doctors it is imperative that global guidelines for giving ... revised. The reason is// that since they might be ... forth by researchers from the United States and Tanzania. They ... cause severe illness and death if they are given to ...
... field of life sciences and biotechnology. Staf Van ... told a seminar that the country has tremendous potential for ... starting with an R&D project in tuberculosis, in collaboration with ... the seminar organized here by the Belgo-Indian Chamber of Commerce ...
Cached Medicine News:Health News:Countries Step up Battle Against Bird Flu 2Health News:Countries Step up Battle Against Bird Flu 3Health News:Europe Seeks Indian Expertise 2
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
Mylar Plate Sealers 100/Box...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
For use with 96-well plates, catalog # 410150...
Medicine Products: